Showing 2711-2720 of 3039 results for "".
- STAAR Surgical’s EVO Viva Presbyopia Correcting Lens Receives CE Mark Approvalhttps://modernod.com/news/staar-surgicals-evo-viva-presbyopia-correcting-lens-receives-ce-mark-approval/2477977/STAAR Surgical announced that its EVO Viva presbyopia correcting implantable collamer lens (ICL) has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva,” from its European Noti
- Gilead’s Veklury Gains Conditional EU Approval for Treatment of COVID-19https://modernod.com/news/gileads-veklury-gains-conditional-eu-approval-for-treatment-of-covid-19/2477970/Gilead Sciences said Friday that the European Commission granted conditional approval to Veklury (remdesivir) for the treatment of SARS-CoV-2 infection. The company noted that the clearance, which was based on a rolling review that began in April, follows a
- Remdesivir, the First Coronavirus Drug, Gets a Price Taghttps://modernod.com/news/remdesivir-the-first-coronavirus-drug-gets-a-price-tag/2477953/Remdesivir, the first drug shown to be effective against the coronavirus, will be distributed under an unusual agreement with the federal government that establishes nonnegotiable prices and prioritizes American patients, health officials announced on Monday, accordin
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistancehttps://modernod.com/news/how-regenerons-covid-19-antibody-cocktail-cuts-the-risk-of-resistance/2477920/When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last w
- Aurinia Completes Patient Enrollment In Phase 2/3 Trial of Voclosporin for the Treatment of Dry Eyehttps://modernod.com/news/aurinia-completes-patient-enrollment-in-phase-2-3-trial-of-voclosporin-for-the-treatment-of-dry-eye/2477914/Aurinia Pharmaceuticals announced it has completed enrollment for the phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Voclosporin’s proven mechanism of action as a novel calcineurin inhibitor gives us
- Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings for GA Secondary to AMDhttps://modernod.com/news/iveric-bio-announces-positive-zimura-18-month-data-supporting-the-12-month-efficacy-findings/2479517/Iveric bio announced positive 18 month results from the company’s first phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The 18 month data support
- Five Coronavirus Treatments In Developmenthttps://modernod.com/news/five-coronavirus-treatments-in-development/2479524/Right now, there is only one drug shown by rigorous scientific testing to be helpful for treating COVID-19. That drug is the antiviral medication called remdesivir, made by Gilead Sciences. But remdesivir’s proven benefits